A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Clinical trial NCT00639002 · COMPLETED

Trial details

NCT number: NCT00639002
Sponsor: Incyte Corporation
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2008-03-01
Primary completion: 2010-07-01
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.